The 'Micro-Nuclear Bomb' for Precision Oncology: How Do Alpha Emitters Redefine the Paradigm of Cancer Therapy?

• In situ effect (cellular level): Alpha particles instantly shatter the DNA double helix in cancer cells via dual mechanisms—direct ionization and indirect oxidative stress. The complex, irreparable damage caused by this high linear energy transfer (LET) directly drives cells toward apoptosis. • Bystander effect (microenvironmental level): This is the well-known 'radiation-induced bystander effect' (RIBE). Even neighboring cells not directly hit by alpha particles can receive lethal damage signals—via gap-junction communication, reactive oxygen species (ROS) transmission, or soluble mediators such as exosomes—triggering cascading cell death. • Systemic effect (organismal level): Alpha radiation can also induce 'immunogenic cell death' (ICD) in tumor cells, prompting the release of danger-associated molecular patterns (DAMPs) that activate the body’s immune system—including dendritic cells and cytotoxic T lymphocytes. This effectively launches systemic immune surveillance while eliminating local tumors, generating an 'abscopal effect' against distant metastatic lesions. Pioneers: The Breakthrough Paths of ²²⁵Ac and ²²³Ra Among numerous alpha-emitting radionuclides, actinium-225 (²²⁵Ac) and radium-223 (²²³Ra) stand out as the two most representative 'clinical pioneers'. ²²³Ra is currently the only alpha-emitting radiopharmaceutical approved globally for clinical use (Xofigo®). Its natural bone-seeking property enables precise targeting of bone metastases in prostate cancer, significantly extending overall survival in patients with symptomatic bone-metastatic castration-resistant prostate cancer (mCRPC)—marking a milestone in the clinical translation of alpha emitters. In contrast, ²²⁵Ac is regarded as the next-generation 'long-lived assassin'. With a half-life of ~10 days and the capacity to emit four alpha particles sequentially along its decay chain, its cytotoxic potency is extraordinary. Radiopharmaceuticals such as ²²⁵Ac-PSMA have demonstrated remarkable potential in patients with treatment-resistant prostate cancer and neuroendocrine tumors. However, ²²⁵Ac faces significant challenges: its decay daughters may undergo 'recoil', detaching from the targeting vector and dispersing systemically—leading to adverse effects such as salivary gland toxicity and myelosuppression. Moreover, dosimetry for alpha emitters is vastly more complex than for conventional drugs. Bridging the Gap: Four Key Challenges and a Three-Tier Development Pathway Despite its immense promise, translating alpha emitters from the laboratory into broad clinical practice requires overcoming four systemic hurdles: 1. Insufficient stable supply: High-purity medical-grade alpha emitters (e.g., ²²⁵Ac) are extremely scarce worldwide, with fragile supply chains severely constraining clinical research and drug development. 2. Suboptimal in vivo stability: Ensuring radiopharmaceuticals remain intact and bound to their targeting vectors throughout complex systemic circulation—thereby minimizing off-target toxicity—is a core challenge in drug design. 3. Lack of standardized dosimetry frameworks: The highly heterogeneous energy deposition of alpha particles at the microscopic scale renders traditional macroscopic dosimetry models obsolete; urgently needed are novel, multi-scale, standardized dosimetry evaluation systems. 4. Scarcity of high-quality clinical evidence: Most alpha-emitter drugs remain in early-phase or exploratory clinical trials; large-scale, multicenter randomized controlled trials are essential to robustly confirm long-term efficacy and safety.

Next-Generation Precision Radiopharmaceutical Completes First-in-Human Dosing and Follow-up

As the 'vanguard' of the radiopharmaceutical platform jointly developed by 3D Medicines and Keyi Sheng Pharmaceutical, 3D1015—designed with a novel dual-mechanism and precision molecular architecture—delivered outstanding preclinical results, truly achieving 'greater accuracy, stronger efficacy, and enhanced safety': • More precise tumor targeting: Its binding affinity for the PSMA target is approximately twice that of同类 already-marketed products, enabling missile-like precision in recognizing and binding tumor cells. • More durable cytotoxic effect: Intracellular uptake in tumor cells increased by ~1.5-fold, and drug exposure in tumor tissue surged ~3.2-fold—achieving 'high exposure and prolonged retention' specifically at the tumor site. • Markedly improved safety profile: Only one-quarter the radionuclide dose required by同类 products achieves comparable tumor suppression. In animal studies, no histopathological damage was observed across any major organs—significantly reducing potential radiation toxicity to healthy tissues. • Greener, cost-efficient, and patient-friendly: Reduced radionuclide usage translates not only into higher patient throughput per treatment facility and lower radioactive waste generation, but also opens avenues for flexible pricing and improved patient access. 🏥 Clinical Progress: Strategic, Robust Development Addressing Unmet Clinical Needs This first-in-human dosing study is an investigator-initiated trial (IIT), led by Professor Chun-Jing Yu of the Department of Nuclear Medicine at the Affiliated Hospital of Jiangnan University.

Nuclide Therapeutics builds leaner radiopharmaceuticals

1 day ago

Nuclide Therapeutics raised £5 million to initiate its first clinical trial for anticancer radiopharmaceuticals utilizing theranostic molecules. The London-based firm targets dosing its first patient by year-end.

cen

2026-10-12

Nuclide Therapeutics builds leaner radiopharmaceuticals

Nuclide Therapeutics builds leaner radiopharmaceuticals

FAQ